Share this article:

Irvine-based Edwards Lifesciences Corp. is buying privately held CardiAQ Valve Technologies Inc. for $350 million in cash and up to $50 million in regulatory milestone payments.

CardiAQ also is based in Irvine and is developing less-invasive replacement mitral heart valves.

Get the latest OC business and Coronavirus updates

Edwards said it bought CardiAQ to expand its portfolio of those products. The company stopped enrolling patients in a clinical trial for its own less-invasive mitral valve known as Fortis about two months ago.

The company released its news Friday afternoon, after markets closed. Edwards’ shares were up 2% today in midday trading to a market value of $16.2 billion.